Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: Disease overview • Pneumonia • Types of pneumonia PART 06: Market landscape • Market overview • Market size and forecast PART 07: Pipeline analysis PART 08: Market segmentation by drug class • Antibacterial drug • Antiviral drugs • Others PART 09: Geographical segmentation • HAP drugs market in Americas • HAP drugs market in EMEA • HAP drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Combination therapy for the treatment of HAP • Growing preference for accurate diagnosis of disease • Rising R&D for effective treatment against superbugs/MDR microorganisms PART 13: Vendor landscape • Competitive landscape PART 14: Key vendor analysis • GlaxoSmithKline • Merck • Novartis • Pfizer • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Classification of pneumonia Exhibit 02: Types of HAP Exhibit 03: Symptoms and tests of HAP Exhibit 04: Global HAP drugs market snapshot Exhibit 05: Global HAP drugs market 2016-2021 ($ millions) Exhibit 06: Opportunity analysis of HAP drugs market Exhibit 07: Five forces analysis Exhibit 08: Key pipeline molecules by vendors Exhibit 09: Pipeline landscape Exhibit 10: Segmentation of global HAP drugs market by drug class Exhibit 11: Global HAP drugs market share by drug class 2016 and 2021 Exhibit 12: Uses and side effects of antibacterial drug Exhibit 13: Global HAP antibacterial drugs market 2016-2021 ($ millions) Exhibit 14: Causative microorganisms and empiric treatment Exhibit 15: Brand mixtures for piperacillin-tazobactam Exhibit 16: Global HAP antiviral drugs market 2016-2021 ($ millions) Exhibit 17: Global HAP others drugs market 2016-2021 ($ millions) Exhibit 18: Segmentation of global HAP drugs market based on geography 2016 and 2021 Exhibit 19: Global HAP drugs market revenue by geography 2016-2021 ($ millions) Exhibit 20: Market scenario in Americas Exhibit 21: HAP drugs market in Americas 2016-2021 ($ millions) Exhibit 22: Market scenario in EMEA Exhibit 23: HAP drugs market in the EMEA 2016-2021 ($ millions) Exhibit 24: Market scenario in APAC Exhibit 25: HAP drugs market in the APAC 2016-2021 ($ millions) Exhibit 26: Average percentage distribution of transplants by organ in US 1988-2016 Exhibit 27: Competitive structure analysis of global HAP drugs market 2016 Exhibit 28: GlaxoSmithKline: Key highlights Exhibit 29: GlaxoSmithKline: Strength assessment Exhibit 30: GlaxoSmithKline: Strategy assessment Exhibit 31: GlaxoSmithKline: Opportunity assessment Exhibit 32: Merck: Key highlights Exhibit 33: Merck: Strength assessment Exhibit 34: Merck: Strategy assessment Exhibit 35: Merck: Opportunity assessment Exhibit 36: Novartis: Key highlights Exhibit 37: Novartis: Strength assessment Exhibit 38: Novartis: Strategy assessment Exhibit 39: Novartis: Opportunity assessment Exhibit 40: Pfizer: Key highlights Exhibit 41: Pfizer: Strength assessment Exhibit 42: Pfizer: Strategy assessment Exhibit 43: Pfizer: Opportunity assessment

GlaxoSmithKline, Merck, Novartis, Pfizer, Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.